Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Think of training, communication and community as the three vertices of a triangle. Lose any one, and the structure collapses ...

Opening a business credit card is often framed as a way to separate expenses and earn basic rewards, but the real value can ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

Zohran Mamdani is now mayor of New York City, and the Left’s old ways of relating to elected officials won’t cut it. We need ...

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

The companies that survive will look less like pyramids and more like swarms: small, autonomous AI-first pods that move and ...

MIT researchers have developed a new method for designing 3D structures that can be transformed from a flat configuration ...

The following is the Dec. 30, 2025, Congressional Research Service report, Navy Guided Missile Battleship (BBG[X]) Program: ...

Dec 8 (Reuters) - Structure Therapeutics (GPCR.O), opens new tab said on Monday its obesity pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study, driving the company ...